JAAD international · 2025
A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vekovska Kamelia, Imko-Walczuk Beata, Tichý Martin, Draelos Zoe Diana, Cetkovska Petra, Rich Phoebe, Weglowska Jolanta
Аннотация
BACKGROUND: DMB-3115 is a biosimilar to Stelara (hereinafter referred to as ustekinumab).
OBJECTIVES: To evaluate the clinical similarity of DMB-3115 with ustekinumab in patients with moderate-to-severe plaque psoriasis.
METHODS: In this phase 3, randomized, double-blind, parallel-arm study, adults with moderate-to-severe plaque psoriasis were randomized to receive DMB-3115 or ustekinumab (weeks 0-28), followed by re-randomization to continue treatment or switch to DMB-3115 (weeks 28-52). The primary efficacy endpoints were percent change in Psoriasis Area and Severity Index score from baseline to week 8 and week 12. The safety endpoint was the incidence of adverse events.
RESULTS: A total of 598 patients were randomized to receive DMB-3115 (n = 299) or ustekinumab (n = 299). The least squares mean percent changes in Psoriasis Area and Severity Index score from baseline to week 8 were 77.5% (DMB-3115) and 77.9% (ustekinumab), and from baseline to week 12 were 87.6% (DMB-3115) and 87.9% (ustekinumab). Rates of treatment-emergent adverse events were similar between treatments during period 1 (DMB-3115: 47.5%; ustekinumab: 49.8%) and period 2 (DMB-3115: 18.7%; ustekinumab: 21.2%; switched to DMB-3115: 18.3%).
LIMITATIONS: Data were only through week 52.
CONCLUSIONS: DMB-3115 showed a similar clinical efficacy and safety profile to ustekinumab in patients with moderate-to-severe plaque psoriasis.
OBJECTIVES: To evaluate the clinical similarity of DMB-3115 with ustekinumab in patients with moderate-to-severe plaque psoriasis.
METHODS: In this phase 3, randomized, double-blind, parallel-arm study, adults with moderate-to-severe plaque psoriasis were randomized to receive DMB-3115 or ustekinumab (weeks 0-28), followed by re-randomization to continue treatment or switch to DMB-3115 (weeks 28-52). The primary efficacy endpoints were percent change in Psoriasis Area and Severity Index score from baseline to week 8 and week 12. The safety endpoint was the incidence of adverse events.
RESULTS: A total of 598 patients were randomized to receive DMB-3115 (n = 299) or ustekinumab (n = 299). The least squares mean percent changes in Psoriasis Area and Severity Index score from baseline to week 8 were 77.5% (DMB-3115) and 77.9% (ustekinumab), and from baseline to week 12 were 87.6% (DMB-3115) and 87.9% (ustekinumab). Rates of treatment-emergent adverse events were similar between treatments during period 1 (DMB-3115: 47.5%; ustekinumab: 49.8%) and period 2 (DMB-3115: 18.7%; ustekinumab: 21.2%; switched to DMB-3115: 18.3%).
LIMITATIONS: Data were only through week 52.
CONCLUSIONS: DMB-3115 showed a similar clinical efficacy and safety profile to ustekinumab in patients with moderate-to-severe plaque psoriasis.